CVS partners with ProKidney to enroll patients for phase 3 cell therapy trial
02 Feb 2023
Cell TherapyPhase 3AcquisitionClinical ResultImmunotherapy
Preview
Source: FierceBiotech
To help fund the study, ProKidney hauled in $825 million as part of a merger last January with Social Capital Suvretta Holdings Corp. III.
CVS Health Clinical Trial Services, a unit of the pharmacy giant CVS, has signed up to begin enrolling patients for ProKidney’s phase 3 trial of its ReACT cell therapy designed to treat chronic kidney disease.
Under the agreement, CVS Health will recruit participants at 39 sites by using a machine learning model to identify patient populations that align with trial inclusion/exclusion criteria, the company said in a Jan. 31 media advisory. Financial details weren’t disclosed.
ProKidney picked up ReACT when it acquired inRegen for $62 million in 2019. In 2021, the company presented data on 51 type 2 diabetic chronic kidney disease patients who received image-guided injections of autologous renal progenitors across two midphase trials. The treatment is designed to slow, stabilize and reverse decline in kidney function.
If proven effective, ProKidney has forecast the eligible patient population at about 4.4 million. If the company can penetrate just 1% of the addressable market, it has said it could reap as much as $16 billion with the treatment going for $360,000 a patient.
To help fund the study, the company hauled in $825 million as part of a merger last January with Social Capital Suvretta Holdings Corp. III, a SPAC set up by billionaire investor Chamath Palihapitiya and Suvretta Capital.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.